ORAMED PHARMACEUTICALS INC logo

ORMP

ORAMED PHARMACEUTICALS INC

$8.31

Earnings Summary

Revenue
$0Mn
Net Profits
$0.01Mn
Net Profit Margins
1035.19%

Highlights

Revenue:

ORAMED PHARMACEUTICALS INC’s revenue fell -99.9% since last year same period to $0Mn in the Q3 2022. On a quarterly growth basis, ORAMED PHARMACEUTICALS INC has generated -99.9% fall in its revenue since last 3-months.

Net Profits:

ORAMED PHARMACEUTICALS INC’s net profit jumped 100.1% since last year same period to $0.01Mn in the Q3 2022. On a quarterly growth basis, ORAMED PHARMACEUTICALS INC has generated 100.07% jump in its net profits since last 3-months.

Net Profit Margins:

ORAMED PHARMACEUTICALS INC’s net profit margin jumped 203.17% since last year same period to 1035.19% in the Q3 2022. On a quarterly growth basis, ORAMED PHARMACEUTICALS INC has generated 166.24% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the ORAMED PHARMACEUTICALS INC post its latest quarter earnings

EPS Estimate Current Quarter
-0.25
EPS Estimate Current Year
-0.25

Highlights

EPS Estimate Current Quarter:

ORAMED PHARMACEUTICALS INC’s earning per share (EPS) estimates for the current quarter stand at -0.25 - a -2.46% fall from last quarter’s estimates.

EPS Estimate Current Year:

ORAMED PHARMACEUTICALS INC’s earning per share (EPS) estimates for the current year stand at -0.25.

Key Ratios

Key ratios of the ORAMED PHARMACEUTICALS INC post its Q4 2022 earnings

Earning Per Share (EPS)
-0.18

Highlights

Earning Per Share (EPS):

ORAMED PHARMACEUTICALS INC’s earning per share (EPS) jumped 12.2% since last year same period to -0.18 in the Q4 2022. This indicates that the ORAMED PHARMACEUTICALS INC has generated 12.2% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2016-01-13
-0.18
-0.21
-16.67%
2015-11-25
-0.18
-0.19
-5.56%

Company Information

Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsulefor the treatment of diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901.

Organisation
ORAMED PHARMACEUTICALS INC
Headquarters
1185 Avenue of the Americas, New York, NY, United States, 10036
Employees
0
Industry
Health Technology
CEO
Nadav Kidron

Trading and brokerage services provided by

Banking and Remittance services provided by

Technology services provided by : Finzoomers Services Private Limited

Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*